Le Donanemab, candidat médicament contre la maladie d'Alzheimer episode artwork

EPISODE · May 22, 2023 · 14 MIN

Le Donanemab, candidat médicament contre la maladie d'Alzheimer

from Focus

Le Donanemab, candidat médicament contre la maladie d’Alzheimer, valide une étude clinique de phase 3. Développé par le laboratoire Lilly, le donanemab est un anticorps monoclonal dirigé contre la protéine amyloïde. L’étude clinique de phase 3 TRAILBLAZER-ALZ 2 remplit ses attentes et montre un ralentissement du déclin cognitif et fonctionnel chez des patients atteints d’une maladie d’Alzheimer à un stade léger.

Episode metadata supplied by the publisher feed · Published May 22, 2023

Embed this episode

Ready to play

Le Donanemab, candidat médicament contre la maladie d'Alzheimer

0:00 14:46

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Focus?

This episode is 14 minutes long.

When was this Focus episode published?

This episode was published on May 22, 2023.

Can I download this Focus episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!